Lily L. Nguyen
YOU?
Author Swipe
View article: TO BE OR NOT TO BE A PI: ADVICE FOR TRAINEES IN THE BIOMEDICAL/BASIC SCIENCES
TO BE OR NOT TO BE A PI: ADVICE FOR TRAINEES IN THE BIOMEDICAL/BASIC SCIENCES Open
When a biomedical or basic science doctoral (PhD) student considers whether or not to become a Principal Investigator (PI), they typically base their decisions on anecdotal data from a limited number of faculty mentors. Alternatively, they…
View article: Figure S3 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Figure S3 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression Open
In vivo body weight and PCA plot
View article: Figure S1 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Figure S1 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression Open
WNT3A overexpression
View article: Supplementary Figures and Tables from ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer
Supplementary Figures and Tables from ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer Open
Table S1 - Antibody Details Table S2 - Primer Sequences Table S3 - AP1 shRNA Screen Details Table S4 - Patient Characteristics from Tissue Microarray Table S5 - Transcription factor overlap Figure S1 - Dose response, AP1 activity and AP1 s…
View article: Artificial intelligence chatbots as sources for patient education material on child abuse
Artificial intelligence chatbots as sources for patient education material on child abuse Open
Background: The World Health Organization defines childhood maltreatment as any form of abuse or neglect affecting children under 18 years of age that can cause actual or potential harm. Child abuse is a form of interpersonal trauma that c…
View article: Supplementary Data from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Supplementary Data from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
Overview of supplementary data
View article: Figure S5 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Figure S5 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
In vivo modeling with loss of CBX2 expression and Nanostring pathway analysis
View article: Table S3 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Table S3 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
Nanostring
View article: Table S4 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Table S4 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
TIMERv2
View article: Table S1 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Table S1 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
Antibodies
View article: Figure S4 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Figure S4 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
M1/M2 macrophages convey differential survival outcomes. M1/M2 gating strategy. CD68 gating of monocytes in culture system.
View article: Figure S1 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Figure S1 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
CBX2 binds to promoter regions of cytokine genes and CBX2 is significantly associated with immune signatures.
View article: Table S2 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Table S2 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
Primers
View article: Figure S3 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Figure S3 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
Modulation of CBX2 enhances monocyte infiltration
View article: Figure S2 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Figure S2 from Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma Open
CBX2 expression associates with epithelial state 6. CBX2 protein expression does not correlate with T cell infiltration. CXCL1, 5, and CXCL8 expression correlation with Macrophage M0_CIBERSORT infiltration.
View article: Data from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Data from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Poly ADP-ribose polymerase inhibitors (PARPi) are first-line maintenance therapy for ovarian cancer and an alternative therapy for several other cancer types. However, PARPi-resistance is rising, and there is currently an unmet need to com…
View article: Supplementary Figure 1 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Figure 1 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
GSEA of ID8 Olaparib-resistant (ID8-OR) and sensitive (ID8) ovarian cancer cells.
View article: Supplementary Table 16 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 16 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to Olaparib alone.
View article: Supplementary Table 1 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 1 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Multispectral IHC antibody list
View article: Supplementary Table 14 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 14 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to EZM8266 alone.
View article: Supplementary Table 13 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 13 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to EZM8266 alone.
View article: Supplementary Table 2 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 2 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Flow cytometry antibody list
View article: Supplementary Table 15 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 15 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to Olaparib alone.
View article: Supplementary Table 9 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 9 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to Olaparib alone.
View article: Supplementary Table 8 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 8 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
View article: Supplementary Table 11 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 11 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to DMSO control.
View article: Supplementary Table 5 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 5 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways enriched in ID8-OR cells treated with combinatory UNC0642/Olaparib compared to DMSO control.
View article: Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
View article: Supplementary Table 6 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 6 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to DMSO control.
View article: Supplementary Table 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Supplementary Table 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner Open
Hallmark pathways enriched in ID8-OR cells compared to ID8 cells.